Foghorn Therapeutics vs Precigen
FHTX and PGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FHTX and PGEN compare
Precigen is the larger company, worth 14 times as much as Foghorn Therapeutics ($1.7B against $124M).
On earnings, Foghorn Therapeutics is cheaper: it trades at 29.9× trailing earnings, against 118× for Precigen.
Precigen keeps more of each dollar of sales as profit, with a net margin of 15.6% compared with 8.4% at Foghorn Therapeutics.
Foghorn Therapeutics scores higher on the StockData Score (10 against 6 for Precigen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FHTX | PGEN |
|---|---|---|
| Size and price | ||
| Market cap | $124M | $1.7B |
| Share price | $2.09 | $4.72 |
| Change, 1 year | −52.7% | 18.0% |
| Change, 5 years | −84.7% | 25.5% |
| Beta (5Y) | 1.87 | 1.64 |
| Employees | 106 | 20 |
| StockData Score | ||
| Total score | 10 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 2 | 4 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 29.9× (better) | 118× |
| P/S | 1.1× (better) | 10.8× |
| P/B | – | 20.2× |
| EV/EBITDA | 11.5× (better) | 45.5× |
| FCF yield | −67.4% | −4.4% (better) |
| Fair value | $2.08 | $1.33 |
| Margin of safety | −0.44% (better) | −256% |
| Growth | ||
| Revenue growth (TTM) | 357% | – |
| Revenue growth, 5Y average | 135% (better) | −21.3% |
| Profitability | ||
| Operating margin | 2.1% | 21.4% (better) |
| Net margin | 8.4% | 15.6% (better) |
| FCF margin | −74.6% | −47.4% (better) |
| Return on equity | – | 38.8% |
| Return on invested capital | – | 147% |
| Financial health | ||
| Debt / equity | – | 1.12 |
| Net debt / EBITDA | – | 1.14 |
| Interest coverage | – | 2.8× |
| Current ratio | 4.24 | 5.58 (better) |
| Altman Z-score | −2.66 (better) | −5.17 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 75.6% | 39.2% |
| Held by insiders | 36.3% | 44.9% |
| Insider net buying, 12 months | – | −$32.5M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 6.0% | 22.8% |
Go deeper
- FHTX stock overview
- FHTX income statement
- FHTX valuation and score
- PGEN stock overview
- PGEN income statement
- PGEN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.